Gland Pharma Ltd

Gland Pharma announced that Satyanarayana Murthy Chavali, DIN: 00142138, Independent Director of the Company has tendered resignation to his directorship in the Company with effect from 15 June 2026.

Great Eastern Shipping Company Ltd, Premier Energies Ltd, ICICI Prudential Life Insurance Company Ltd, Amber Enterprises India Ltd are among the other stocks to see a surge in volumes on NSE today, 18 May 2026.Gland Pharma Ltd notched up volume of 52.97 lakh shares by 14:14 IST on NSE, a 27.13 fold spurt over two-week average daily volume of 1.95 lakh shares. The stock rose 14.05% to Rs.2,130.80. Volumes stood at 1.42 lakh shares in the last session.Great Eastern Shipping Company Ltd clocked volume of 152.92 lakh shares by 14:14 IST on NSE, a 9.69 times surge over two-week average daily volume of 15.78 lakh shares. The stock gained 10.07% to Rs.1,688.30. Volumes stood at 97.54 lakh shares in the last session.Premier Energies Ltd registered volume of 48.25 lakh shares by 14:14 IST on NSE, a 5.44 fold spurt over two-week average daily volume of 8.87 lakh shares. The stock rose 1.56% to Rs.996.90. Volumes stood at 7.51 lakh shares in the last session.ICICI Prudential Life Insurance Company Ltd notched up volume of 56.33 lakh shares by 14:14 IST on NSE, a 5.24 fold spurt over two-week average daily volume of 10.75 lakh shares. The stock slipped 3.02% to Rs.519.45. Volumes stood at 4.82 lakh shares in the last session.Amber Enterprises India Ltd saw volume of 18.39 lakh shares by 14:14 IST on NSE, a 5.13 fold spurt over two-week average daily volume of 3.59 lakh shares. The stock dropped 14.67% to Rs.7,233.00. Volumes stood at 3.79 lakh shares in the last session.Powered by Capital Market - Live

Great Eastern Shipping Company Ltd, Raymond Ltd, Arvind Ltd and Shipping Corporation of India Ltd are among the other gainers in the BSE's 'A' group today, 18 May 2026.Gland Pharma Ltd surged 13.81% to Rs 2124.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 2.25 lakh shares were traded on the counter so far as against the average daily volumes of 14321 shares in the past one month. Great Eastern Shipping Company Ltd soared 10.15% to Rs 1687.5. The stock was the second biggest gainer in 'A' group. On the BSE, 8.78 lakh shares were traded on the counter so far as against the average daily volumes of 1.1 lakh shares in the past one month. Raymond Ltd spiked 7.44% to Rs 488.6. The stock was the third biggest gainer in 'A' group. On the BSE, 2.18 lakh shares were traded on the counter so far as against the average daily volumes of 74378 shares in the past one month. Arvind Ltd exploded 5.45% to Rs 475.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.06 lakh shares were traded on the counter so far as against the average daily volumes of 69959 shares in the past one month. Shipping Corporation of India Ltd spurt 4.86% to Rs 347.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 10.18 lakh shares were traded on the counter so far as against the average daily volumes of 10.2 lakh shares in the past one month. Powered by Capital Market - Live

The key equity benchmarks witnessed sharp sell-off in morning trade mirroring weak global cues. Investor sentiment remained subdued amid uncertainty surrounding geopolitical developments. The rupee depreciated, while Brent crude prices rallied above the $110-per-barrel mark. Nifty hovered below the 23,400 level. Consumer durables shares extend losses for a third consecutive session. At 10:25 IST, the barometer index, the S&P BSE Sensex declined 832.12 points or 1.10% to 74,413.21 The Nifty 50 index dropped 261.20 points or 1.10% to 23,382.30. The broader market underperformed the frontline indices. The BSE 150 MidCap Index tumbled 1.66% and the BSE 250 SmallCap Index dropped 2.57%. The market breadth was negative. On the BSE, 764 shares rose and 3,102 shares fell. A total of 204 shares were unchanged. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 96.2300 compared with its previous close of 95.8100. It also touched an all-time intraday low of 96.25 today. In the commodities market, Brent crude for July 2026 settlement rose $1.83 cents or 1.67% to $111.09 a barrel. Earnings to Watch: Indian Oil Corporation(down 2.42%), Afcons Infrastructure(down 6.87%), Ola Electric Mobility(down 3.17%), Apollo Micro Systems(down 2.16%), Indraprastha Gas(down 1.22%), JSW Cement(down 1.95%), Puravankara(down 1.90%), Sun Pharma Advanced Research Company(down 2.26%), Strides Pharma Science(down 1.81%), Baazar Style Retail (down 5.01%) and Zydus Wellness(down 2.94%) will announce their quarterly earnings today. Buzzing Index: The Nifty consumer durables index tumbled 3.34% to 34,366.50. The index fell 3.42% in the two consecutive trading sessions. Amber Enterprises India (down 13.68%), PG Electroplast (down 5.56%), Blue Star (down 3.8%), Kalyan Jewellers India (down 3.41%), Crompton Greaves Consumer Electricals (down 2.86%), LG Electronics India (down 2.84%), Dixon Technologies (India) (down 2.4%), Havells India (down 2.38%), Bata India (down 2.27%) and Titan Company (down 2.05%) tumbled. Stocks in Spotlight: Gland Pharma surged 12.47% after the pharma company has reported 96.62% increase in consolidated net profit to Rs 366.7 crore on a 22.31% rise in net sales to Rs 1,742.80 crore in Q4 FY26 over Q4 FY25. NCC slipped 5.22% after the company reported an 18.8% drop in consolidated net profit to Rs 206.02 crore in Q4 FY26, compared to Rs 253.82 crore recorded in Q4 FY25.Powered by Capital Market - Live

Revenue from USA aggregated to Rs 980.7 crore (up 25.44% YoY), Europe revenue added up to Rs 381.4 crore (up 36% YoY) and that from Rest of the world was Rs 254.9 crore (up 6% YoY). Sales in Canada, Australia and New Zealand were Rs 58.8 crore (down 2% YoY) and those in India were Rs 67 crore (up 28% YoY). Profit before tax stood at Rs 505.79 crore in Q4 FY26, up by 75.42% from Rs 288.33 crore recorded in Q4 FY25. Consolidated EBITDA stood at Rs 513 crore in Q4 March 2026, registering the growth of 48% YoY with EBITDA margin of 29%. R&D expenses stood at Rs 50.6 crore in Q4 FY26, accounting for 4% of base business revenue, and were primarily directed toward complex product development and filings. During the quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine, taking total US launches in FY26 to 31 products. On the regulatory front, eight ANDA filings were made and 11 approvals were received in Q4 FY26, while FY26 saw 24 filings and 28 approvals, taking cumulative US ANDA filings to 388 (337 approved and 51 pending). The in-house complex pipeline continues to strengthen with six products already launched and three awaiting approval, with complex injectables expected to remain a key long-term growth driver. Under co-development partnerships, 15 products are in development, including seven 505(b)(2) and eight ANDAs, with commercialization expected from FY28. The company also advanced its Ready-to-Use (RTU) bag portfolio with 21 filings, 18 approvals, and 11 products under development, addressing an estimated US market opportunity of $634 million. In the GLP-1 and insulin analog segment, the company launched Liraglutide in the US, with pen/cartridge capacity at 140 million units per annum. Additionally, a new CDMO contract was signed for a complex nano drug delivery system-based injectable in oncology. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, 'Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses including Cenexi. The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing costefficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.' The board has recommended a final dividend of Rs 20 per equity share of face value Rs 1 each (2000%) for FY26. If approved, the dividend will be paid within 30 days from the date of the 48th Annual General Meeting. The record date for determining eligible shareholders has been fixed as Tuesday, August 11, 2026. Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.Powered by Capital Market - Live

Gland Pharma announced that the 48th Annual General Meeting(AGM) of the company will be held on 25 August 2026.

Gland Pharma announced that the Board of Directors of the Company at its meeting held on 15 May 2026, inter alia, have recommended the final dividend of Rs 20 per equity Share (i.e. 2000%) , subject to the approval of the shareholders.

Net profit of Gland Pharma rose 96.57% to Rs 366.68 crore in the quarter ended March 2026 as against Rs 186.54 crore during the previous quarter ended March 2025. Sales rose 22.31% to Rs 1742.79 crore in the quarter ended March 2026 as against Rs 1424.91 crore during the previous quarter ended March 2025. For the full year,net profit rose 47.07% to Rs 1027.32 crore in the year ended March 2026 as against Rs 698.53 crore during the previous year ended March 2025. Sales rose 14.50% to Rs 6430.65 crore in the year ended March 2026 as against Rs 5616.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1742.791424.91 22 6430.655616.50 15 OPM %29.4424.39 -25.3422.59 - PBDT614.46384.09 60 1912.601440.53 33 PBT505.80288.33 75 1488.931062.66 40 NP366.68186.54 97 1027.32698.53 47 Powered by Capital Market - Live

Revenue from USA aggregated to Rs 980.7 crore (up 25.44% YoY), Europe revenue added up to Rs 381.4 crore (up 36% YoY) and that from Rest of the world was Rs 254.9 crore (up 6% YoY). Sales in Canada, Australia and New Zealand were Rs 58.8 crore (down 2% YoY) and those in India were Rs 67 crore (up 28% YoY). Profit before tax stood at Rs 505.79 crore in Q4 FY26, up by 75.42% from Rs 288.33 crore recorded in Q4 FY25. Consolidated EBITDA stood at Rs 513 crore in Q4 March 2026, registering the growth of 48% YoY with EBITDA margin of 29%. R&D expenses stood at Rs 50.6 crore in Q4 FY26, accounting for 4% of base business revenue, and were primarily directed toward complex product development and filings. During the quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine, taking total US launches in FY26 to 31 products. On the regulatory front, eight ANDA filings were made and 11 approvals were received in Q4 FY26, while FY26 saw 24 filings and 28 approvals, taking cumulative US ANDA filings to 388 (337 approved and 51 pending). The in-house complex pipeline continues to strengthen with six products already launched and three awaiting approval, with complex injectables expected to remain a key long-term growth driver. Under co-development partnerships, 15 products are in development, including seven 505(b)(2) and eight ANDAs, with commercialization expected from FY28. The company also advanced its Ready-to-Use (RTU) bag portfolio with 21 filings, 18 approvals, and 11 products under development, addressing an estimated US market opportunity of $634 million. In the GLP-1 and insulin analog segment, the company launched Liraglutide in the US, with pen/cartridge capacity at 140 million units per annum. Additionally, a new CDMO contract was signed for a complex nano drug delivery system-based injectable in oncology. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, 'Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses including Cenexi. The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing costefficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.' The board has recommended a final dividend of Rs 20 per equity share of face value Rs 1 each (2000%) for FY26. If approved, the dividend will be paid within 30 days from the date of the 48th Annual General Meeting. The record date for determining eligible shareholders has been fixed as Tuesday, August 11, 2026. Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. Shares of Gland Pharma fell 1.80% to end at Rs 1,861 on the BSE.Powered by Capital Market - Live

Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1913.1, up 2.27% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 24170.45. The Sensex is at 77285.81, down 0.72%. Gland Pharma Ltd has risen around 9.38% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has risen around 9.03% in last one month and is currently quoting at 24135.5, down 0.01% on the day. The volume in the stock stood at 1.17 lakh shares today, compared to the daily average of 1.32 lakh shares in last one month.The PE of the stock is 25.97 based on TTM earnings ending December 25.Powered by Capital Market - Live